Treatment of dystrophin cardiomyopathies

Area of Science:

• Cardiology
• Genetics
• Neuromuscular Disorders

Background:

• Dystrophinopathies are genetic disorders causing progressive muscle weakness, frequently leading to severe cardiac complications.
• Cardiac disease in dystrophinopathies can range from subclinical to symptomatic, impacting patient prognosis.
• Cardiovascular involvement is a major cause of morbidity and mortality in individuals with dystrophinopathies.

Purpose of the Study:

• To review and synthesize 20 years of research on therapeutic options for cardiovascular disease in dystrophinopathies.
• To discuss current and future perspectives for managing cardiac conditions in this patient population.
• To highlight the importance of integrated care, including noncardiovascular measures.

Main Methods:

• Comprehensive literature review of studies published over the past two decades.
• Analysis of findings related to pharmacologic interventions and supportive care strategies.
• Discussion of emerging molecular therapies and their potential.

Main Results:

• Presymptomatic treatment with ACE inhibitors, ARBs, beta-blockers, and MRAs effectively delays cardiac disease onset.
• Management of symptomatic cardiac disease aligns with general cardiology guidelines and improves outcomes.
• Noncardiovascular interventions like scoliosis management, ventilation, and pain therapy are crucial, especially in advanced stages.

Conclusions:

• Multifaceted treatment approaches, combining guideline-directed medical therapy with supportive care, are essential for improving cardiac outcomes in dystrophinopathies.
• While established therapies are effective, ongoing research into molecular treatments holds promise for future advancements.
• Optimizing cardiac care in dystrophinopathies requires a holistic approach addressing both cardiovascular and noncardiovascular aspects.